The Pharmacokinetics and Pharmacodynamics of Denosumab in Patients with Advanced Solid Tumours and Bone Metastases: A Systematic Review. Sohn W et al. Br J Clin Pharmacol. 2014 Feb 18. doi: 10.1111/bcp.12355. [Epub ahead of print]. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective…
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Dimopoulos MA et al. Leukemia. 2014 Feb 5. doi: 10.1038/leu.2014.60. [Epub ahead of print]. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Engelhardt M et al. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.…
PET/CT studies of multiple myeloma using 18 F-FDG and 18 F-NaF: comparison of distribution patterns and tracers’ pharmacokinetics. Sachpekidis C et al. Eur J Nucl Med Mol Imaging. 2014 Feb 22. [Epub ahead of print]. Inter-laboratory comparison of Beta-2 microglobulin and albumin methods: impact of assay variation on multiple myeloma staging. Fedele PL et al. Pathology. 2014…
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Siegel DS et al. Blood Cancer J. 2014 Feb 21;4:e182. doi: 10.1038/bcj.2014.1. Daratumumab granted breakthrough drug status. Laubach JP et al. Expert Opin Investig Drugs. 2014 Feb 20. [Epub ahead of print]. Anti-CD40-mediated cancer immunotherapy: an update of recent and…
Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity. Tai YT et al. Blood. 2014 Feb 25. [Epub ahead of print]. Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma. Pappa CA et al. Tumour…
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Palumbo A et al. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(13)70609-0. doi: 10.1016/S1470-2045(13)70609-0. [Epub ahead of print]. Lenalidomide and second malignancies in myeloma patients. Pratt G. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(14)70001-4. doi: 10.1016/S1470-2045(14)70001-4. [Epub ahead of print].…
Subcutaneous Bortezomib incorporated into the Bortezomib-Thalidomide-Dexamethasone regimen as part of frontline therapy in the context of autologous stem-cell transplantation for multiple myeloma.
Lok A et al. Haematologica. 2014 Feb 14. [Epub ahead of print]
Long-term outcome of monoclonal (type 1) cryoglobulinemia.
Néel A et al. Am J Hematol. 2014 Feb;89(2):156-61. doi: 10.1002/ajh.23608.
Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
Fawole A et al. Leuk Lymphoma. 2014 Feb 25. [Epub ahead of print].